RecruitingEarly Phase 1NCT07686484

A Trial of HRS-3095 in Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of HRS-3095 in Healthy Participants

Sponsor

Atridia Pty Ltd.

Enrollment

36 participants

Start Date

Jul 27, 2026

Study Type

INTERVENTIONAL

Conditions

Chronic Spontaneous Urticaria

Summary

The purpose of this study is to assess safety, PK, Pharmacodynamic profile of a single dose of HRS-3095 in healthy participants

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HRS-3095, a drug called HRS-3095, and others for people with chronic spontaneous urticaria. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.